KCI등재후보
노령층 급성백혈병의 치료성적 = Clinical Study on Acute Leukemia in the Elderly
저자
이승태(Seung Tae Lee) ; 민유홍(Yoo Hong Min) ; 한지숙(Jee Sook Hahn) ; 장길진(Gil Jin Jang) ; 송준현(Joon Hyun Song) ; 이선주(Sun Ju Lee) ; 고윤웅(Yun Woong Ko)
발행기관
학술지명
권호사항
발행연도
1995
작성언어
-주제어
KDC
500
등재정보
KCI등재후보
자료형태
학술저널
발행기관 URL
수록면
228-238(11쪽)
제공처
소장기관
Objectives: Approximately 40-60% of acute myelogenous leukemia(AML) and 30% of acute lymphoblastic leukemia(ALL) occur in patients over 60 years old. The elderly leukemic patients showed less complete remission rate and shorter survival, and there have not been universal agreements on the desirable anti leukemic therapy for the elderly patients with acute leukemia. We investigated the clinical characteristics and therapeutic outcomes of 22 patients aged 60 or over diagnosed as acute leukemia during the last 5 years. Methods: Between January 1988 and December 1992, 31 patients aged 60 or over among 174 patients with newly diagnosed acute leukemia, were entered into this study. Among 31 elderly patients, 22 patients underwent remission induction chemotherapy. Remission induction chemotherapy in patients with AML consisted of TAD chemotherapy and low dose cytarabine, and patients with ALL received VPD chemotherapy. Clinical characteristics and therapeutic outcomes of the patients were analyzed retrospectively by review of patiet's medical records. Results: 1) Among 174 patients with acute leukemia, 31 patients were aged 60 or over(17.8%), consisted of 27 AML and 4 ALL patients and male to female ratio was 1: 1.1 median age of them was 65 years. There were no differences in hemogram, bone mar- row findings and complications such as infection, bleeding at the time of initial diagnosis between elderly patients and younger patients. 2) Of 22 elderly patients with acute leukemia received remission induction chemotherapy, twelve patients(55%) achieved complete ramission, comparable to that of younger patients(61%). But median duration of disease free survival and overall survival were significantly shorter(143 days vs 549 days, p= 0.001 and 251 days vs 368 days, p=0.008 respectively) in elderly patients. Complete remission rate of 18 elderly patients with AML was 50%, comparable to that of 77 younger patients with AML(64%), but median duration of disease free survival was significantly shorter(144 days vs 625 days, p=0.014). 3) Complete remission was achieved in 6(60%) of 10 elderly patients with AML received TAD induction chemotherapy, comparable to that of younger patients with AML received TAD chemotherapy(62.7 %) and early death rate was also comparable(10% vs 9% ). There was a trend toward longer durations of disease free survival in younger patients compared to that of elderly patients(625 days vs 144 days). Of whom achieved complete remission, 3 elderly AML(50% ) underwent consolidation chemotherapy as postremission chemotherapy and 88% of younger patients with AML underwent consolidation chemotherapy. 4) Of the 8 elderly patients with AML received low dose cytarabine as induction chemotherapy, 3 patients achieved complete remission and median duration of disease free survival was 85 days, trends toward lower remission rate and shorter duration of disease-free survival compared to that of patients received TAD induction chemotherapy(37.5% vs 60%, 85 days vs 144 days, respectively), but early death rate was camparable(12% vs 10% ). 5) There were no differences in durations of neutropenia, thrombocytopenis, transfusion requirement, infection and bleeding of grade 3 of more between elderly and younger patients with AML during remission induction chemtherapy. Elderly AML patients received TAD chemotherapy needed more frequent platelet transfusion compared to elderly patients received low dose cytarabine as induction chemotherapy(60 units vs 38 unit, p=0,045). Conclusion: The complete remission rate of the elderly patients with acute leukemia after remission induction chemotherapy was comparable to that of the younger patients, and further evaluations about more intensive postremission chemotherapy and supportive cares involving the use of hematopoietic growth factors in the elderly may be warranted.
더보기분석정보
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)